IE 11 is not supported. For an optimal experience visit our site on another browser.

Sara G. Miller

Sara G. Miller is the health editor for NBC News, Health & Medical Unit. 

Sara G. Miller is the health editor for NBC News, Health & Medical Unit. 

Latest from Sara G. Miller

Delta, now a 'variant of concern,' accounts for 10 percent of new U.S. cases, CDC says

The change in classification is based on mounting evidence that the variant spreads more easily and causes more severe disease.

Novavax Covid vaccine highly effective in U.S. trials, including against variants, company says

Novavax said it plans to apply to the Food and Drug Administration for emergency use authorization in the third quarter.
9d ago

FDA approves Alzheimer's drug from Biogen, against experts' advice

The approval comes after an independent panel to the FDA urged the agency to reject the drug, which will be sold under the name Aduhelm.

FDA approves controversial Alzheimer's drug – 1st therapy approved since 2003

The approval comes after an independent panel to the FDA urged the agency to reject the Biogen drug.
13d ago

Covid cases in U.S. fall to levels not seen since March 2020

Thanks to vaccinations, experts say, the U.S. is unlikely to see a summer surge on a scale similar to last year.

Don't eat cicadas if you have a seafood allergy, FDA warns

Billions of cicadas are emerging in the Eastern U.S. To some, they're a delicacy. To others, they're a danger.
14d ago

FDA says to not eat cicadas if you have a seafood allergy

Billions of cicadas are emerging in the Eastern U.S. To some, they're a delicacy. To others, they're a danger.

CDC investigating possible link between heart issues, COVID-19 vaccines in young people

The condition, called myocarditis, appears to be mild and tends to go away on its own.
22d ago

CDC looking into possible link between heart problem and Covid vaccines in young people

The condition, called myocarditis, appears to be mild and tends to go away on its own.

Moderna says vaccine safe and highly effective in kids ages 12 to 17

Authorization would give the U.S. a second vaccine available for this younger age group.